This Is the Next Big Opportunity With Drug Stocks
The following video is part of our daily MarketFoolery podcast, in which host Chris Hill and analysts Alex Scherer and Jason Moser discuss business and investing news. In this segment, the guys discuss how big pharmaceutical companies are trying to overcome the rise of generic drugs, how intermediary players like CVS and Walgreen are benefiting, and which smaller pharmaceutical companies could be acquisition targets.
Merck is one of the companies highlighted in The Motley Fool's report on dividend stocks that are your best bet to beat inflation. It's called "13 High-Yielding Stocks to Buy Today," and you can get access to it right now at no cost. Simply click here -- it's free.
At the time this article was published Chris Hillowns shares of Pfizer. The Motley Fool owns shares of National Oilwell Varco and Exelixis.Motley Fool newsletter serviceshave recommended buying shares of Exelixis, Pfizer, and National Oilwell Varco. Try any of our Foolish newsletter servicesfree for 30 days. We Fools don't all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.
Copyright © 1995 - 2011 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.